A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo
Open Access
- 1 December 1982
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 46 (6) , 904-911
- https://doi.org/10.1038/bjc.1982.300
Abstract
The hypoxic cell radiosensitizing properties of nimorazole have been investigated in a C3H mammary carcinoma transplanted to the feet of C3D2F1. The results have been compared with those obtained with misonidazole (MISO) in the same animal tumour system. For single-dose irradiation in air, nimorazole gives an enhancement ratio (ER) of approximately 1.4, independent of the dose of drug administered over the range 0.1-1.0 mg/g. MISO yields a similar ER at the 0.1 mg/g level but, unlike nimorazole, shows a steep dose-response curve with an ER of 2.2 when given in a concentration of 1.0 mg/g. No such dose-response relationship is seen with nimorazole despite the fact that tumour and plasma concentrations of the 2 drugs have an identical dose relationship. With irradiation given in 5 daily fractions, nimorazole and MISO at a dose of 0.3 mg/g per fraction both show an ER of approximately 1.3. The high drug doses used in single-fraction radiation experiments in animals bear little relation to those applicable to clinical practice since these would result in unacceptable toxicity. The results of the present studies are therefore of interest as nimorazole is potentially less toxic than MISO in humans but demonstrates similar radiosensitizing properties at clinically relevant dose levels.Keywords
This publication has 22 references indexed in Scilit:
- Nitroimidazole neurotoxicity: Are mouse studies predictive?International Journal of Radiation Oncology*Biology*Physics, 1982
- Initial pharmacology and toxicology of intravenous desmethylmisonidazoleInternational Journal of Radiation Oncology*Biology*Physics, 1982
- Clinical experience with nitroimidazoles as radiosensitizersInternational Journal of Radiation Oncology*Biology*Physics, 1982
- The value of adjuvant misonidazole in the definitive irradiation of advanced head and neck squamous cancer: An rtog pilot study (#78-02)International Journal of Radiation Oncology*Biology*Physics, 1981
- Analysis of the basic 5-nitroimidazole nimorazole in blood by reversed-phase high-performance liquid chromatography, and its application to pharmacokinetic studies in individual miceJournal of Chromatography B: Biomedical Sciences and Applications, 1979
- Misonidazole—A drug for trial in radiotherapy and oncologyInternational Journal of Radiation Oncology*Biology*Physics, 1979
- Structure-activity Relationships in the Development of Hypoxic Cell RadiosensitizersInternational Journal of Radiation Biology, 1979
- The radiosensitizing effect of metronidazole and misonidazole (Ro–07–0582) on a human malignant melanoma grown in the athymic mutant nude mouseThe British Journal of Radiology, 1978
- Radiosensitizers of hypoxic cells in solid tumoursCancer Treatment Reviews, 1976
- Studies on antiprotozoans—III: Isolation, identification and quantitative determination in humans of the metabolites of a new trichomonacidal agentBiochemical Pharmacology, 1971